Prospective Evaluation of Circulating Tumour DNA (ctDNA) as Molecular Monitoring Tool and Prognostic Biomarker in Resectable Pancreatic Adenocarcinomas
- Conditions
- C25Malignant neoplasm of pancreas
- Registration Number
- DRKS00010992
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Key inclusion criteria are resectable pancreatic adenocarcinoma and curatively intended, macroscopically complete (R0/R1) resection.
Exclusion Criteria
Key exclusion criteria are Stage IV metastatic disease diagnosed prior to or during surgery and Non-resectable tumour or macroscopically incomplete (R2) resection. Histology other than primary adenocarcinoma is also not included. Other key exclusion criteria are malignancies diagnosed within the previous five years of diagnosis (except non-melanoma skin cancer and carcinoma in situ of the cervix uteri).
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method